3rd May 2016 07:42
LONDON (Alliance News) - Evgen Pharma PLC on Tuesday said the first patient has been dosed in its phase 2 clinical trial of SFX-01, a treatment for aneurysmal subarachnoid haemorrhage, which is a form of stroke.
The drug is a synthetic version of sulforaphane, a known neuroprotective and anti-cancer agent.
The phase 2 trial will recruit 90 patients, half to be dosed with SFX-01 and the other with the current standard treatment.
Evgen Chief Executive Stephen Franklin said aneurysmal subarachnoid haemorrhage is a "rare and devastating condition" and said the start of the trial marks a "key milestone" for the company.
Evgen shares were untraded early Tuesday, having last traded at 19.55 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
EVG.L